DUSP4 UP in '2 micromolar LMP-420' vs 'none'
SLC16A6 UP in '2 micromolar LMP-420' vs 'none'
Analysis of '2 micromolar LMP-420' vs 'none'
EGR1 DOWN in '2 micromolar LMP-420' vs 'none'
LDLRAD4 UP in '2 micromolar LMP-420' vs 'none'
UBE2J1 DOWN in '2 micromolar LMP-420' vs 'none'
CACNA1A DOWN in '2 micromolar LMP-420' vs 'none'
FOSL2 UP in '2 micromolar LMP-420' vs 'none'
GALNT16 UP in '2 micromolar LMP-420' vs 'none'
SESN3 UP in '2 micromolar LMP-420' vs 'none'
LY9 UP in '2 micromolar LMP-420' vs 'none'
LRRC32 UP in '2 micromolar LMP-420' vs 'none'
(Sample) cell type/chronic lymphocytic leukemia cell
DUSP10 UP in '2 micromolar LMP-420' vs 'none'
TNFRSF17 DOWN in '2 micromolar LMP-420' vs 'none'
IGHM DOWN in '2 micromolar LMP-420' vs 'none'
IGHG1 DOWN in '2 micromolar LMP-420' vs 'none'
[original title] LMP-420: a novel purine nucleoside analogue with potent cytotoxic effects for chronic lymphocytic leukemia cells and minimal toxicity for normal hematopoietic cells. LMP-420 induces cytotoxicity and apoptosis to CLL cells in vitro without any negative effects to normal immune cells. This gene expression experiment compares CLL cells treated with LMP-420 versus media alone to investigate the mechanism of action of LMP-420. CLL cells from 13 patients were treated with LMP-420 or media for 24 hours, then RNA was extracted and assayed on U133Plus2 GeneChips.